Phaseline

Companies › Sutro Biopharma

Sutro Biopharma: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
STRO-004
Tissue Factor (TF) antagonist; antibody-drug conjugate targeting TF-expressing cancer cell
F3Phase 1Head and Neck Squamous Cell Carcinoma HNSCCDec 2027
STRO-006
ITGB6-targeting antibody-drug conjugate
ITGB6Phase 1Head & Neck Squamous Cell CarcinomaFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07227168STRO-004Phase 1Head and Neck Squamous Cell Carcinoma HNSCCOncologyDec 2027
NCT07807345STRO-006Phase 1Head & Neck Squamous Cell CarcinomaOncologyFeb 2028

From the company's SEC filings

Cash and short-term investments of $164m on 2026-06-30; operating cash outflow about $163m a year; runway about 12 months at that burn, to Jul 2027

Press releases filed as 8-K in the last year:

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

F3 (1) ITGB6 (1)

Companies with the same targets

Pfizer Adcendo ApS

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.